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Eradicating hepatitis C: Are novel screening strategies for people who inject
drugs cost-effective?
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A B S T R A C T
Background: In developed countries, people who inject drugs (PWID) have a high prevalence of hepatitis C virus
(HCV), yet they are often under-diagnosed. The World Health Organization has set 2030 as a target year for HCV
elimination. To meet this target, improving screening in convenient community settings in order to reach in-
fected undiagnosed individuals is a priority. This study assesses the cost-effectiveness of alternative novel
strategies for diagnosing HCV infection in PWID. Methods: A cost-effectiveness analysis was undertaken to
compare HCV screening at needle exchange centres, substance misuse services and at community pharmacies,
with the standard practice of detection during general practitioners’ consultations. A decision tree model was
developed to assess the incremental cost per positive diagnosis, and a Markov model explored the net monetary
benefit (NMB) and the cost per Quality Adjusted Life Years (QALYs) gained over a lifetime horizon. Results:
Needle exchange services provided a 7.45-fold increase in detecting positive individuals and an incremental cost
of £12,336 per QALY gained against current practice (NMB £163,827), making this the most cost-effective
strategy over a lifetime horizon. Screening at substance misuse services and pharmacies was cost-effective only
at a £30,000/QALY threshold. With a 24% discount to HCV treatment list prices, all three screening strategies
become cost-effective at £20,000/QALY. Conclusions: Targeting PWID populations with screening at needle
exchange services is a highly cost-effective strategy for reaching undiagnosed HCV patients. When applying
realistic discounts to list prices of drug treatments, all three strategies were highly cost-effective from a UK NHS
perspective. All of these strategies have the potential to make a cost-effective contribution to the eradication of
HCV by 2030.
Introduction
Hepatitis C virus (HCV) is a blood-borne virus that, if not treated,
can cause serious and potentially life-threatening damage to the liver.
New HCV treatments can cure over 95% patients (Asselah, Marcellin, &
Schinazi, 2018), allowing cured patients to achieve a life expectancy
equivalent to the general population. However, most chronic HCV in-
fections are asymptomatic and are therefore only diagnosed in the later,
most severe stages of the disease, where cure is less likely. In 2016, the
World Health Organization (WHO) set 2030 as a target for HCV elim-
ination (World Health Orrganization, 2016), followed by various
countries setting even more ambitious elimination deadlines, such as
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2025 in England (APPG, 2018) and 2024 in Scotland (Health Protection
Scotland, 2019). This has encouraged governments to make treatments
more widely available, and subsequently, the number of patients re-
ceiving HCV treatment has increased worldwide (WHO, 2018). Whilst
there have been vast improvements in HCV drug development, the
availability of treatment alone is not enough to achieve WHO targets.
Enhanced diagnosis and screening strategies are also required
(Schröeder et al., 2019).
In the developed world, those most at risk of HCV infection are
people who injects drugs (PWID), particularly individuals with unsafe
injecting practices, such as sharing injecting equipment. In the UK
143,000 people are living with chronic HCV (Public Health England,
2019) and it is estimated that 90% of them have a history of injecting
drug use (NICW, 2012). Yet, this number is considered to be only the
“tip of the iceberg” as nearly half of people infected with HCV remain
undiagnosed (Dillon, Barclay, Fraser, & Hayes, 2018; Public Health
England, 2019). Therefore, to reach the 2030 goal, understanding how
to prioritize screening within high-risk populations to reach infected
undiagnosed individuals is crucial. In this regard, new models of care
based on a complementary involvement of traditional and non-tradi-
tional sites of screening have been designed to increase patient en-
gagement in HCV testing and treatment. These non traditional sites of
screening include a variety of community settings and points of care.
Given the relative newness of these sites of screening there is a need to
understand their cost, cost-effectiveness and implications.
The aim of this study was to evaluate the cost-effectiveness of al-
ternative screening strategies for targeting and diagnosing PWID for
HCV infections using Tayside (Scotland, UK) as a case study. In recent
years, Scotland, and in particular Tayside, has piloted a variety of novel
screening strategies. Scotland's Hepatitis C Action Plan (Goldberg
David., Innes, & Dillon, 2019; Goldberg et al., 2008), outlined strategies
such as moving HCV screening closer to high-risk individuals, including
PWIDs, in order to optimise diagnosis and engagement in care. This
analysis assessed three alternative screening strategies for HCV detec-
tion in PWID that have been piloted in NHS Tayside, Scotland, and
compares them to the current UK standard practice of detection during
a General Practitioner (GP) consultation.
Methods
Screening strategies & model overview
The strategies we analysed were part of an extensive multipronged
model of care for HCV detection developed in Tayside, Scotland. The
key difference between the three novel strategies and the standard care
was the location/point of care where the screening took place. Novel
locations were: a) substance misuse services (SMS), b) needle exchange
services, c) community pharmacies providing opiate substitute thera-
pies and injecting equipment. Standard care was screening during GP
appointment (see Table 1 for strategies’ details). All the strategies were
designed to simplify the cascade of care for patients, moving the point
of care closer to high-risk individuals and streamlining the screening
process, relying on needle exchange workers, nurses or pharmacists
rather than doctors. In Tayside, these three novel strategies have all
been implemented simultaneously and alongside the standard screening
strategy, comprising a pilot of a single complex model of care. The
baseline comparator was the current standard care practice in Scotland
to detect HCV, which was a screening at a GP practice based on
symptoms or high-risk factors. Patients in every strategy differed by (1)
attrition across the HCV cascade of care in the short-term (2) demo-
graphics, and (3) treatment uptake (see Tables 2 and 3 for details).
Testing comprises a HCV antibody test (either dried blood spot test or
venous blood test) and a confirmatory PCR test for antibody positive
individuals. The PCR is a venous blood test which is more expensive
than the antibody test, but provides a confirmed diagnosis of active
infection. Different tests require a different amount of time to obtain
results, and consequently, this translated into different dynamics and
attrition within the cascade. The number of people attending services
differed across the strategies, as did the number of tests taken, positive
tests results and user-engagement beyond initial testing. Inputs (pre-
valence, effectiveness, resource use estimates) for the model were de-
rived from observational data from the pilot studies and published lit-
erature and were then supported by the knowledge of clinical experts.
The model was parameterised to the Scottish and UK context through
published life expectancy estimates, utility values, unit cost values and
data on PWID-HCV prevalence in Scotland. Model design was based on
clinical expert advice and previously published studies analysed in a
literature review of economic evaluation of screening strategies for
HCV detection (see Supporting Information for details). The needle
exchange centre strategy data were obtained from the Cairn Centre
Harm Reduction Service in Dundee, which serves approximately 50% of
the people who inject drugs in Tayside (NHS Tayside audit data).
Pharmacy data were derived from 33 pharmacies dispensing opiate
substitute therapies and injecting equipment which provide HCV
screening across NHS Tayside. The Dundee Integrated Substance Misuse
Service provided the data for SMS service. General Practices across NHS
Tayside provided data for the standard practice arm, however, data
from this strategy referred to the general population and not to current
PWIDs only. Since there is evidence suggesting that there is a higher
propensity to screen PWIDs for HCV by GPs (Datta, Horwood, Hickman,
& Sharp, 2014; McLeod et al., 2017), and also a likely difference in
compliance in the cascade of care, a counterfactual strategy for current
PWIDs was built. The counterfactual was based on the average of all the
three observed PWID strategies and the available data for screening at
GPs for the general population, this estimate was then validated or
adjusted based on clinicians’ opinions (Table 3). Assumptions regarding
the likelihood of a PWID going to a specific testing location were based
on advice from clinical experts directly involved in the PWID model of
care. The economic analysis initially compares each strategy against the
GP strategy (standard care) (pairwise comparison). Strategies are also
analysed incrementally to provide the relative cost-effectiveness and
Table 1
HCV Screening strategies.
Screening Strategies:
General practitioner (GP): During a routine GP appointment, there is clinical
suspicion that the patient may have HCV and a venous antibody test is requested.
The blood sample is sent away for testing and the patient called back in a few
days with the results. If positive, a PCR test is also requested. If the result is
positive, this is fed back with a further contact to the patient in a few days by the
requesting healthcare worker and onward referral is made to HCV specialist
services.
Substance Misuse Services: Clients who are being assessed to begin receiving Opiate
Substitute Therapies (OST) by the Tayside Substance Misuse Service (SMS), or
who are already on an OST, are offered a hepatitis C test. A dried blood spot
(DBS) test is taken by an addiction worker at the SMS. Positive antibody tests on
DBS are then directly referred to a HCV specialist nurse on site taking routine
blood tests and HCV PCR, or working close by in a Needle exchange centre (5 min
walking time). If the person is confirmed to have HCV, the patients is contacted
in few days to start the treatment, either initiated by the community pharmacists
dispensing OST or the HCV specialist nurses in the outreach clinics.
Pharmacies: Clients attending participating community pharmacies to collect their
OST are opportunistically offered a HCV test if not previously tested. Clients with
positive DBS antibody tests receive a subsequent confirmatory HCV RNA and
genotype testing, and their results are delivered in a few days. If HCV infection is
confirmed, clients are referred to a HCV service and then they initiate treatment
via the community pharmacist or are referred to the HCV specialist nurses for
review and treatment in a HCV outreach clinic. Pharmacies running screenings
receive fees per patients for using tests, administrative costs and to manage the
risk of ordering high cost medications.
Needle exchange centres: People attending the needle exchanges are offered HCV
testing via DBS by trained staff at the needle exchange service. If positive,
patients are referred to a HCV nurse who take routine bloods tests, including
HCV RNA, on site. If the HCV RNA is positive the clients are then contacted in
few days and invited to attend an outreach clinic at the needle exchange centre to
be started on HCV eradication.
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net monetary benefit of each strategy.
Model structure
We used a deterministic model of HCV treatment and screening to
compare the four different screening strategies in the Tayside area. The
model comprised a short-term decision tree covering the first year and a
Markov model extending it to a lifetime horizon.Theshort-term diag-
nosis outcomes fed into the long-term analysis (see Fig. 1). The eco-
nomic analysis took the UK NHS perspective. The decision tree illus-
trates the HCV cascade of care: the propensity of going to a point of care
(screening strategy), type of test offered, result delivery, and if antibody
positive a confirmatory PCR test. The main differences across strategies
over the short-term were: professional/personnel delivering the
screening and type of test (dried blood spot (DBS) or venous sample),
timing in delivering the confirmatory test and patients’ characteristics
(demographics and attrition across the HCV cascade of care). The
outcome of the short-term analysis was the incremental cost per addi-
tional case detected.
A previously published Markov model (Younossi et al., 2015) was
adapted and used to model the treatment and subsequent management
pathway which, after screening, followed the natural history of HCV
patients over a lifetime horizon. In the model, individuals who had been
diagnosed with active HCV infection could be treated or could decline
treatment/not respond. If successfully treated, individuals entered into
the treatment arm achieving a sustained virologic response (SVR),
where they had a much lower probability of progressive liver disease.
Patients who were HCV positive but were either untreated, or the
treatment failed, moved into the ‘no treatment’ arm (see Fig. 1). Pa-
tients who remained undetected in the short-term model also moved
into the ‘no treatment’ arm in the Markov model, where the natural
course of untreated HCV disease progresses (Fig. 1). Patients in both
arms could enter the model from mild (stage F0) to severe fibrosis
stages (stage F4) and could then potentially progress in the disease
moving then further into decompensated cirrhosis (DCC); hepatocel-
lular carcinoma (HCC); liver transplant (LT); post-liver transplant
(LT+1) and death. Outcomes for the lifetime analysis are reported in
terms of the incremental cost-effectiveness ratio (ICER) and net
monetary benefit (NMB), based on a willingness to pay threshold of
£20,000 per quality-adjusted life year gained (QALY) (NICE 2012).
The different screening strategies determined the outcome of the
short-term model (proportion of people detected and treated out of the
total number of infected) and their average age at detection.
Specifically, the observational data showed a significant difference in
mean age of the people accessing the different screening strategies and,
therefore, this was applied in the model (Table 1). Thus, all the stra-
tegies entered in the model at the same age (32 years, the average age
of the population in the strategy with the earliest starting age) but
started the screening according to their average age at detection. Dis-
ease stage progresses annually with transition probabilities in the
model. Hence, strategies with higher average age of screening had a
more advanced disease stage at detection (see Supporting Information
for more details). A sensitivity analysis using observational data for the
initial liver disease severity stage at the time of detection was
undertaken (see supporting information and sensitivity analysis sec-
tion). The length of each cycle in the Markov model was one year. After
each cycle patients could remain in their state or change state in line
with the model transition probabilities. As the long-term model is an
extrapolation of the short-term results, the data coming from strategies’
observations were limited to the aggregate demographics of the people
screened. The treatment uptake rate, transition probabilities across
Markov states, utility values for each state and mortality rates came
from published literature relevant to the UK HCV population.
Parameters
Prevalence and transition probabilities
Data on the prevalence of current PWID used in the short-term
model came from published literature (Dillon, Barclay, Fraser, & Hayes,
2018; Hutchinson, Bird, & Goldberg, 2005; Surveillance report. hepa-
titis c antibody positive cases in scotland: results to 31 december 2017,
2017) and experts’ advice from clinicians involved in the Tayside model
of care (Table 3). The probability of being screened and offered the test
was also based on clinicians’ opinion. Data on prevalence were derived
from a combination of sources and adjusted to year 2017 according to
the Health Protection Scotland epidemiology figures of the HCV trend
rate over years (Surveillance report. hepatitis c antibody positive cases
in scotland: results to 31 december 2017, 2017). This was validated by
the clinicians involved in designing the strategies. The probability of
every node following the offer or acceptance of the first test (IgG) was
driven by observational data from the pilot strategies in Tayside,
Scotland. The probability at every node was the proportion of people
continuing in the cascade of care. Evidence for the PWID population
screened at GPs was based on the average of the figures of the three
strategies regarding PWID, with the data coming from the NHS Tayside
general population and obtained from GP practices. Sensitivity and
specificity of preliminary antibody tests depends on the type of test (a
venous sample or DBS). The sample size of every strategy derived from
observational data on the number of people tested and recorded in each
strategy between 2015 and 2017.
Treatment, mortality and health utilities
HCV treatments applied in the model are the direct-acting antiviral
(DAA) regimens recommended by Healthcare Improvement Scotland
(Dillon, Barclay, Fraser, & Hayes, 2018). Overall, in Tayside the pre-
valence of HCV genotype 3 amongst the infected patients is assumed to
be 70% and genotype 1 is 30%, in accordance with the local data.
Treatment varies based on genotype and on being treatment naïve or
experienced (Dillon, Barclay, Fraser, & Hayes, 2018). Treatment regi-
mens were modelled as if all the patients were treatment naïve, a worst-
case scenario where all patients were treatment experienced was con-
sidered in the sensitivity analysis. Background mortality in the Markov
model wasadjusted with the standardised mortality ratio for the PWID
population, in accordance with their lower life expectancy
(Mathers et al., 2013). Parameters for HCV progression and health
utilities for each Markov state were taken from previous published
studies (using UK values) (Castelnuovo et al., 2006; McEwan, Kim, &
Yuan, 2013; Younossi et al., 2018) (Table 3).
Table 2
Cohorts' figures.
Observational data Individuals with lgG positive1 HCV+ detected No. individuals with HCV stage assessment Average age
GP for general population 99 75 60 432
SMS 91 54 24 37
Needle Exchange Centres 61 48 1043 32.5
Pharmacies 77 22 21 39
1 IgG positivity is intended as initial of the cascade of care, HCV+ detection is the end of the short-term model.
2 Figure referring to the general population, counterfactual is the result of the average of the other three strategies with the general population.
3 The higher number of reported disease stage observations is due to repeat assessments during the 2011–17 period.
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Table 3
Main input parameters.
Parameter Mean value Distribution Source
Population characteristics
PWID prevalence 0.43 Beta(α=56.57,β=74.9) (Dillon, Barclay, Fraser, & Hayes, 2018; Hutchinson et al., 2005; Surveillance report.
hepatitis c antibody positive cases in scotland: results to 31 december 2017, 2017)
Cascade of care
PWID chance of going to GP 0.25 Norm(µ=0.25,σ=0.015) Assumption
Chance of being screened for all the
venues except GP
0.7 Norm(µ=0.7,σ=0.043) Assumption
PWID GP - Chance of being tested if
positive
0.20 Norm(µ=0.2,σ=0.012) Assumption
IgG -Venous sample sensitivity 0.98 (Colin et al., 2001)
IgG -Venous sample specificity 0.99 (Colin et al., 2001)
DBS/oral fluid IgG sensitivity 0.92 (Colin et al., 2001; Judd et al., 2003)
DBS/oral fluid IgG specificity 0.99 (Judd et al., 2003)
GP Counterfactual- IgG+ but PCR- 0.138 Beta(α=12,β=75) NHS Tayside
GP Counterfactual- treatment
acceptance
0.907 Beta(α=68,β=7) NHS Tayside
GP Counterfactual- PCR acceptance 0.88 Beta(α=88,β=11) NHS Tayside
SMS- IgG+ but PCR- 0.18 Beta(α=12,β=54) NHS Tayside
SMS- treatment acceptance 0.63 Beta(α=45,β=26) NHS Tayside
SMS- PCR acceptance 0.73 Beta(α=66,β=25) NHS Tayside
Needle Exchange- IgG+ but PCR- 0.22 Beta(α=6,β=27) NHS Tayside
Needle Exchange- treatment acceptance 0.76 Beta(α=103,β=32) NHS Tayside
Needle Exchange- PCR acceptance 0.9 Beta(α=27,β=3) NHS Tayside
Pharmacies- IgG+ but PCR- 0.59 Beta(α=50,β=72) NHS Tayside
Pharmacies- treatment acceptance 0.95 Beta(α=21,β=1) NHS Tayside
Pharmacies- PCR acceptance 0.68 Beta(α=49,β=21) NHS Tayside
Transition probabilities
F0 to F1 0.117 Uniform±20% (Coffin, Scott, Golden, & Sullivan, 2012; Thein, Yi, Dore, & Krahn, 2008)
F1 to F2 0.085 Uniform±20% (Coffin et al., 2012; Thein et al., 2008)
F2 to F3 0.120 Uniform±10% (Coffin et al., 2012; Thein et al., 2008)
F3 to F4 0.116 Uniform±20% (Coffin et al., 2012; Thein et al., 2008)
F3 to HCC 0.002 (Coffin et al., 2012; McEwan et al., 2013; Thein et al., 2008)
F4 to HCC 0.014 Beta(α=1.93,β=136.11) (McEwan et al., 2013; Younossi et al., 2018)
F4 to DC 0.039 Beta(α=14.62,β=360.17) (Martin et al., 2012, 2016)
DC to HCC 0.014 Beta(α=1.93,β=136.11) (Martin et al., 2012, 2016; Younossi et al., 2018)
DC to LT 0.030 Beta(α=6.53,β=210.99) (Martin et al., 2012)
DC to D 0.130 Beta(α=147.03,β=983.97) (Martin et al., 2012)
HCC to LT 0.103 (McGarry et al., 2012; Martin et al., 2012)
HCC to D 0.427 Beta(α=117.1,β=155.23) (McGarry et al., 2012; Martin et al., 2012; Younossi et al., 2018)
LT to D 0.210 Beta(α=16.28,β=61.23) (Martin et al., 2012)
LT1 to D 0.057 Beta(α=22.9,β=378.88) (Martin et al., 2012)
SVR-F3 to SVR F2 0.267 (Younossi et al., 2015)
SVR-F4 to SVR F3 0.076 (Younossi et al., 2015)
SVR relative risk F4 to HCCa 0.24 (Morgan et al., 2013; Younossi et al., 2015)
SVR relative risk F3 to HCCa 0.24 (Morgan et al., 2013)
SVR relative risk F4 to DCa 0.086 (Morgan et al., 2013)
Treatment success, genotype 1 (F0-3)a 0.97 (Ahmed et al., 2018)
Treatment success, genotype 1 (F4)a 0.95 (Ahmed et al., 2018)
Treatment success, genotype 3 (F0-3)a 0.98 (Foster et al., 2015)
Treatment success, genotype 3 (F4)a 0.93 (Foster et al., 2015)
Utilities
F0-F1 0.77 Beta(α=521.24,β=155.69) (Martin et al., 2012)
F2-F3 0.66 Beta(α=168.25,β=86.87) (Martin et al., 2012)
F4 0.55 Beta(α=521.24,β=155.69) (Martin et al., 2012)
HCC 0.45 Beta(α=123.75,β=151.25) (Martin et al., 2012)
DC 0.45 Beta(α=123.75,β=151.25) (Martin et al., 2012)
LT 0.45 Beta(α=123.75,β=151.25) (Martin et al., 2012)
SVR F0-F1 0.82 Beta(α=65.87,β=14.46) (Martin et al., 2012)
SVR F2-F3 0.72 Beta(α=58.06,β=22.28) (Martin et al., 2012)
SVR F4 0.61 Beta(α=58.05,β=37.11) (Martin et al., 2012)
Main Short term unit cost (£ per patient)
Dried blood spot test 11.55 NHS Tayside(2018)
PCR test 50.25 NHS Tayside(2018)
IgG venous blood sample 12.50 NHS Tayside(2018)
Specialist nurse time 15.25 (Curtis & Burns, 2017)
GP consultation time 28.00 (Curtis & Burns, 2017)
Costs (£ per year)
DC 12,234 PPIxGamma(α=36.02,β=253.16) (Castelnuovo et al., 2006)
HCC 10,904 PPIxGamma(α=18.11,β=448.8) (Castelnuovo et al., 2006)
LT 36,664 PPIxGamma(α=89.75,β=304.5) (Castelnuovo et al., 2006)
LT+1 1858 PPIxGamma(α=15.22,β=91.01) (Castelnuovo et al., 2006)
F4 treated people monitoring expenses 284 NHS reference costs for Ninewells procedures
Treatment costs per cycle
Gen1-cirrhotic 36,500 BNF,2019 prices
(continued on next page)
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Costs
Cost data were obtained directly from Ninewells Hospital (Tayside)
and NHS Reference costs in accordance with Ninewells procedures.
Costs included in the model are those relevant from the UK NHS per-
spective. This comprised the cost of screening, equipment, testing,
treatment and monitoring (Table 3). All costs were adjusted to 2017
prices and discounted annually at 3.5% (NICE 2012). Patients detected
and treated at F0, F1, F2 or F3 do not incur further costs. Following
treatment patients detected at F4 were assumed to be monitored an-
nually, in accordance with Ninewells Hospital (Tayside) procedures.
Scottish national guidelines (Dillon, Barclay, Fraser, & Hayes, 2018)
determined the treatment used in the model. Treatment cost was ob-
tained from the British National Formulary. In line with the original
model (Martin et al., 2012), individuals with undetected or detected but
not treated HCV, were assumed to have no treatment related costs in
the model until reaching decompensated cirrhosis. This is the stage
when liver disease becomes severe and symptomatic and therefore,
patients are assumed to receive care.
Sensitivity analysis
A Probabilistic Sensitivity Analysis (PSA) was undertaken using
1000 iterations Monte Carlo Simulation in which all key parameter
inputs to the model were randomly sampled from a predefined prob-
ability distribution. The probability distributions mean values and
standard errors used for the PSA for the parameters are reported in
Table 3. One-way sensitivity analyses were also performed on the
following parameters to evaluate further the impact of uncertainty in
assumptions and other areas on results:
• 0–100% discount applied to the list price of HCV drug treatments.
• Assumption of 100% treatment uptake after diagnosis.
• 100% increase in offering IgG test by GPs.
• 50% decrease in initial prevalence.
• Substitution of the model diseases stage prevalence at detection with
the observable data.
• Same age (32 years) and same initial stage of disease across all the
strategies.
• Treatment regimens assuming all patients were treatment experi-
enced.
• The different likelihood of going to a specific screening site for
PWIDbased on the number of positive PCR collected in each
screening setting from 2015 to 2017.
Scenario analysis
The PWID population has a high risk of re-infection due to their
high risk lifestyle (needle and syringe sharing) (Falade-
Nwulia, Sulkowski, Merkow, Latkin, & Mehta, 2018; Schulkind et al.,
2019), yet re-infection rates are uncertain and vary based on a variety
of risk factors. To account for reinfection in the model, a scenario
analysis was undertaken whereby an additional transition probability
was introduced from the SVR states to the same non-treated state for all
the PWID strategies. In effect, this means that after incurring the cost of
Table 3 (continued)
Parameter Mean value Distribution Source
Gen1-noncirrhotic 36,500 BNF,2019 prices
Gen3-cirrhotic 39,740 BNF,2019 prices
Gen3-noncirrhotic 25,987 BNF,2019 prices
Standardised mortality ratio for PWID 14.68 (Mathers et al., 2013)
a Treatment success rate and relative risk parameters do not have distributions, and they were added with no uncertainty into the PSA
Fig. 1. Short term decision tree & lifetime Markov Model. Markov model structure taken from (Younossi et al., 2018) and adapted to this study. Short term model:
IgG= preliminary test to detect HCV antibodies. Individuals can be IgG positive, but they can clear on their own the virus resulting PCR negative (therefore not
infected). PCR= confirmatory test. Long term model: DCC= decompensated cirrhosis, D=death, F0-4= metavir score (liver fibrosis stage) in ascending order of
severity, HCC= hepatocellular carcinoma, LT= liver transplant, LT+1= after one year of liver transplant, SVR=sustained virologic response.
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treatment, some patients were then immediately re-infected and con-
tinue to progress in the model as if they had received no treatment. It
was assumed that once an individual was re-infected after treatment,
the individual did not receive further treatment in the future. The re-
infection rate adopted for this scenario was based on the most recent
data on HCV re-infection for PWID in Tayside (Rossi et al., 2018). This
study mapped reinfection within the same needle exchange centre
analysed for the study. To account for a lower reinfection risk in older
individuals (Rossi et al., 2018) (and the consequent reduction in
sharing propensity), the transition probability of reinfection used was
assumed to decrease over time in accordance with the data (Rossi et al.,
2018). The reinfection rate at 33 years was 0.10 (average age of
screening at needle exchange pathway), and at 40 years was 0.06 (age
for PWID going to GP). The rate of re-infection decreased on an average
of 7.5% per year.
Results
Offering tests at needle exchange centres was associated with a
10% (7.45-fold) increase in cases detected compared to the standard
care (Table 4a). Whereas, for SMS and pharmacies the increase was
8.4% and 7.8%, respectively. Whilst the needle exchange strategy cost
£13 per case detected more than screening at GP practices, the most
expensive strategy was screening at pharmacies at £17.30 and the
cheapest was SMS with £9.47. The highest and lowest strategies in
terms of cost per HCV+ detected are a symptomatic screening at GPs
(£335) and screening at SMS (£150), respectively. Screening at SMS
cost £112 per any additional person screened compared to GP.
Screening at needle exchange services had an ICER of £124 per addi-
tional HCV+ detected against GP. Each strategy had a low ICER value
and could be considered cost-effective compared to the GP current
practice in a pairwise comparison. Using an incremental approach
(Table 4b), screening at SMS was the most cost-effective strategy in the
short term.
The results in the long-term differ from the short-term. Indeed,
looking at the cost per QALY in a life time horizon rather than at the
cost per case detected, needle exchange was the most cost-effective
alternative setting to a screening at GPs. This is because the proportion
of positively detected HCV cases incurred costs, quality of life and life
expectancy implications over the patient lifetime. In the lifetime ana-
lysis only screening at needle exchange was cost-effective with an in-
cremental cost-effectiveness ratio value of £12,336/QALY,generating
the greatest QALY gain (0.4 QALYs) in the population due to a higher
number of people treated compared to its comparator. Based on the
incremental analysis, both SMS and pharmacies were dominated by
needle exchange and GP.
Sensitivity & scenario analyses
The results of the PSA suggest that screening at needle exchange was
highly likely to be a cost-effective strategy. However, there was con-
siderable uncertainty surrounding the cost-effectiveness of both
screening at pharmacies and SMS, respectively, depending on the
chosen willingness to pay (WTP) for QALY gains (Fig. 2) (CEAC in
Supporting Information).
Assuming all strategies began screening at the same age (32 years)
and, with the same disease severity, made both SMS and Pharmacy
strategies cost-effective, bringing them below the £20,000/QALY
threshold (Fig. 3b). Alternative assumptions regarding the probability
of going to a different point of care based on the number of PCR+, as
well as having a 100% treatment uptake, had little impact on the cost-
effectiveness results. Using the observed value for disease severity at
detection made all the strategies cost-effective at less than £5000/QALY
compared to the screening at GP (Fig. 3b). An increase in treatment
price, such as using a worst-case scenario where allindividuals were
treatment experienced and require costlier treatments, led to screening
at needle exchange being the only cost-effective strategy (Fig 3b).
However, if a 24% discount on the UK list price of treatments was
applied, there was the potential for all strategies to be considered cost-
effective. (Fig. 3a).
When reinfection rates were introduced to the base case model, all
strategies were not cost effective at a threshold of £20,000 per QALY.
Discussion
In this study we compared each of the three HCV screening strate-
gies both individually and incrementally against the current practice.
To the best of our knowledge, this is the first time that data coming
from multiple current vanguard screening strategies have been com-
pared to shed light on how current screening policies are performing in
tackling HCV from a health economic perspective. We found that novel
strategies for targeting and screening PWID populations are likely to be
cost-effective compared to current standard care.
While screening at needle exchange resulted in the highest number
of cases being detected, the lowest cost per case detected was associated
with SMS. Hence, screening at SMS was the most cost effective
Table 4a
Short- and long-term results- pairwise comparison (every strategy vs current practice).
Short term
Strategy Expected Strategy cost £ Proportion of detected (% out of total
positive)
Cost per positive
detected
Incremental cost £ Incremental Effect ICER
GP PWID 5.61 0.02 (3.9%) 335.07
SMS 15.08 0.10 (23.4%) 149.82 9.47 8.4% 112
Needle Exchange 19.11 0.12 (28.9%) 152.98 13.49 10.8% 124
Pharmacies 22.91 0.09 (21.9%) 242.16 17.30 7.8% 222
Long term
Strategy Cost £ (95% Cred Inter.) QALY (95% Cred Inter.) Incremental cost Incremental QALY ICER NMB (£)
GP PWID 5143 (3327,7591) 8.29 (7.93,8.66) – – – 160,737
SMS 8032 (5692,10,190) 8.42 (8.05,8.78) 2889 0.13 22,518 160,414
Pharmacies 9321 (7012, 11,320) 8.44 (8.09,8.79) 4178 0.15 27,402 159,609
Needle Exchange 10,117 (7532,11,787) 8.70 (8.31,9.04) 4974 0.40 12,336 161,814
Reinfection scenario
GP PWID 5162 (3333,7608) 8.29 (7.91,8.62) – – – 160,589
SMS 8156 (5758,10,371) 8.37 (8.00,8.74) 2995 0.08 35,813 159,267
Pharmacies 9465 (7104,11,526) 8.40 (8.04,8.76) 4304 0.11 39,969 158,439
Needle Exchange 10,369 (7629,12,140) 8.47 (8.07,8.82) 5207 0.19 28,000 159,102
ICER = Incremental Cost-Effectiveness Ratio, NMB = Net Monetary Benefit, QALY = Quality Adjusted Life Years. NMB calculated using a willingness to pay of
£20,000/QALY. NMB= [Effectiveness*(Willingness to pay)-Costs]. Due to rounding, Figures throughout the table may not add up to the totals. There may be
discrepancies between the reported ICER, NMB and those totals
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Table 4b
Short- and long-term results- incremental comparison.
Short term
Strategy Expected Strategy
cost £
Proportion of detected (% out
of total positive)
Cost per positive detected Incremental cost £ Incremental Effect ICER
GP PWID 5.61 0.02 (3.9%) 335.07
Pharmacies 22.91 0.09 (21.9%) 242.16 Strictly dominated by
SMS
SMS 15.08 0.10 (23.4%) 149.82 9.47 0.08 118.38
Needle Exchange 19.11 0.12 (28.9%) 242.16 4.03 0.02 201.05
Long term
Strategy Cost £ (95% Cred
Inter.)
QALY (95% Cred Inter.) Incremental cost Incremental QALY ICER NMB (£)
GP PWID 5143 (3327,7591) 8.29 (7.93,8.66) – – –
SMS 8032 (5692,10,190) 8.42 (8.05,8.78) extended dominated by Needle
Exchange and GP PWID
Pharmacies 9321 (7104,11,526) 8.44 (8.09,8.79) strictly dominated by SMS
Needle Exchange 10,117 (7532,11,787) 8.70 (8.31,9.04) 4974 0.4 12,336 161,814
Reinfection scenario
GP PWID 5162 (3333,7608) 8.29 (7.91,8.62) – – –
SMS 8156 (5758,10,371) 8.37 (8.00,8.74) extended dominated by Needle
Exchange and GP
Pharmacies 9465 (7104,11,526) 8.40 (8.04,8.76) extended dominated by Needle
Exchange and GP
Needle Exchange 10,369 (7629,12,140) 8.47 (8.07,8.82) 5207 0.19 28,000 159,102
Fig. 2. Incremental cost effectiveness plane with all the strategies against the current standard practice - Base case scenario. Table represent the probability of being
cost effective for every strategy against the current standard practice (GP) at different willingness to pay.
F. Manca, et al. International Journal of Drug Policy 82 (2020) 102811
7
approach to detect current PWID positive patients, followed by
screening at needle exchange services. Indeed, these strategies, which
rely on mostly non-clinician personnel are typically less costly.
Although in the long term the higher number of people screened and
detected incurred greater costs, screening current PWID at needle ex-
change remained cost-effective. The difference in cost-effectiveness
across strategies between short and lifetime horizon was mainly due to
disease stage, which was accounted for in the long term. This suggests
that screening at an older age, which is more likely in strategies in-
volving SMS and pharmacies, detects disease at more severe stages and,
therefore, with more advanced liver damage and lower quality of life
after treatment. Screening intensification at GPs for current PWID
would increase both the number of people detected, but also the overall
cost of the strategy in the short-term. However, even if more people
were screened, the average older age of screening would increase the
cost of treatment more than the potential gain in QALY in the long term
(see long term sensitivity analysis, Fig. 3b). Nevertheless, age was not
the sole driver of the cost-effectiveness results in the lifetime model:
holding age constant across different strategies, standard screening at
the GPs remained the least effective alternative due to the lower de-
tection rate coming from the short-term model (see sensitivity analysis).
In the reinfection scenario, only screening at needle exchange cen-
tres was below £30,000/QALY. This may be the result of our data
coming from a small sample that reported higher reinfection rates than
previous publications (Aspinall et al., 2013; Dimova et al., 2013).
Moreover, the reinfection model was designed to consider only treated
individuals who could be re-infected if sharing injecting equipment
with those who are infected, reducing the cost-effectiveness in the
model. However, given the model's static framework, it did not consider
that augmenting the number of treated individuals in a population
would reduce the pool of potential HCV positive people spreading the
infection. A possible change in the propensity of sharing needles after
treatment was not taken into account either. In a dynamic scenario,
both these last two effects could potentially counterbalance the pre-
vious. We suggest that the outcome of our reinfection scenario should
be interpreted as an extremely conservative scenario. It is reasonable to
expect that with these policies the overall HCV prevalence within the
PWID population will decrease. Our results show that changes in pre-
valence would impact mainly short-term dynamics, but not affect long
term conclusions (Fig 3b).
All the strategies involved the same macro population and belonged
to the same model of care piloted and performed in Tayside. However,
it is reasonable to expect that different screening sites could identify
different subpopulations, which do not necessarily overlap. For in-
stance, the regular client of a pharmacy is likely to have a different
profile than the needle exchange frequenter (same reasoning for SMS).
Unfortunately, the lack of data, in particular regarding the PWID access
to differing points of care, means that we were unable to track the
Fig. 3. 3a. Line chart illustrating ICER for screening by the percentage of treatment listed price for baseline and re-infection scenario. 3b. One-way sensitivity
analysis.
F. Manca, et al. International Journal of Drug Policy 82 (2020) 102811
8
different clients’ profile. Thus, we analysed the PWID population as if it
was homogeneous across strategies. The result was that screening at
needle exchange was the most cost-effective option. Nevertheless, there
will likely be challenges for the implementation of screening through a
single strategy, such as capacity constraints at a single point of care,
individuals’ preferences or the availability of a specific test setting, and
hence complementary strategies should be considered. To allow for
more comprehensive policy suggestions based on observational evi-
dence, governments should invest in data collections across local PWID
community services (e.g. to map different client profiles to estimate the
weight of every strategy within the model of care) to provide stronger
evidence of every strategy's characteristics at local levels. Policymakers
should run central policies which include a mix of the most cost-ef-
fective approaches reflecting the availability of specific points of care
and the prevalence of user profile in a specific area.
The sensitivity analysis of the treatment list price shows that the
main driver for the cost-effectiveness analysis is the treatment cost. In
Scotland and many other regions and countries there is a nationally
published list price for HCV medications, and from these there are
confidential negotiations that reduce the costs dependant on volume of
sales and other factors. From personal communications reductions in
costs are the norm and in the HCV field they are well in excess of 50%.
Therefore, analyses with discounted drug prices on the official listed
price by the UK British National Formulary (BNF 2019) should be a
more realistic representation of the costs in clinical practice. In this
regard, a discount of 24% of the treatment listed price made all the
strategies in each scenario cost-effective at a £20,000 WTP threshold.
For the re-infection scenario, at discount equal to or greater than 48%
made all strategies cost-effective. Given the importance of treatment
price in our analyses, in countries where the actual HCV treatment price
is still high for the health care providers, further negotiation with the
industry is crucial to reach sustainable cost-effectiveness strategies. In
contexts where this interaction between stakeholders already happens,
such as in Scotland where reductions in list costs are the norm,
screening strategies are likely to be cost-effective. Hence, the focus of
policymakers should be more on stratagems to detect individuals at
early stage of disease, improving engagement within the cascade of care
and limiting reinfection.
Strengths and limitations
This study sought to evaluate the cost-effectiveness of the current
and potential new approaches to tackle HCV detection. Our findings
confirm that alternative strategies to detect positive PWID can be highly
cost-effective. Specifically, approaches that detect at earlier stages of
infection (which is likely to mean younger individuals) and capture a
higher number of individuals are expected to be the most cost-effective.
However, there were also several limitations to our study.
Firstly, the representativeness of the model of care is unclear as it
was based on a small sample of potential screening locations and on a
sample of the drug-user population in the Tayside area. Moreover, this
was a retrospective study using for the first time a multitude of stra-
tegies from a relatively small area. Even if these findings can provide
insights to policy makers, results may have a local perspective. For
national recommendations, prospective cohort studies need to be im-
plemented, which could overcome the potential bias affecting the se-
lection of our counterfactual. In this regard, given the need to reflect
regional differences, central policies should be tailored on evidence
from a local level.
Secondly, the lack of data on a few key parameters, such as the
proportion of people visiting the different screening sites, led to the use
of secondary data sources. Unfortunately, there is currently limited data
available on some community services. Therefore, our HCV test ac-
ceptance/offer rate was based on expert and clinical opinions of per-
sonnel working within the services described in our study. However,
this was addressed by testing our assumptions in one-way sensitivity
analyses and using wide uncertainty in the PSA.
Thirdly, the reinfection scenario analysis did not take into account a
herd immunity factor. Indeed, in small areas, there could be a decrease
in incidence since treating people reduces the number of infected
people able to transmit the infection. However, it should be noted that
usually the reinfection rate is not modelled in screening models and,
when it is, it can be very sensitive to authors’ assumptions (Geue et al.,
2015). We decided to include the prospect of reinfection in a scenario
analysis in a static setting. As already mentioned, our reinfection model
should be interpreted as an extremely conservative scenario.
Lastly, the model was static and, beyond reinfection, it did not allow
for a migration from the PWID status. However, the lack of data re-
garding this potential transition, the fact that these were retrospective
cohorts referring to heterogeneous samples, and the desire to provide a
snapshot of an ongoing policy in its first years of operation, led us to
build a static model in line with most of the recent literature on cost-
effectiveness of HCV treatment (Chhatwal, He, & Lopez-Olivo, 2016)
and screening (Geue et al., 2015). Since the static nature of the analysis
does not allow direct assessment of the cost-effectiveness of the stra-
tegies over time, a plausible decrease in prevalence due to these policies
was considered in the sensitivity analysis.
This study presents a comprehensive analysis of a regional HCV
screening strategy in the UK and provides insights that need to be ad-
dressed to ensure cost-effective decision-making at a national level. For
instance, treatment cost has a crucial role in determining whether
screening strategies targeting a PWID population are likely to be cost-
effective. Overall, the cost-effectiveness of a strategy increases in the
short-term with the engagement in the cascade of care, and in the long
term with early diagnosis (associated with a point of care screening at
younger ages) and treatment cost. In Tayside, screening at all the al-
ternative screening sites seems to respect these requirements. Our re-
sults found that screening at needle exchange was likely to be the most
cost-effective strategy in the long-term. Indeed, with the application of
a plausible discount to the treatment price, the study demonstrates how
all the screening strategies could be considered highly cost-effective
when compared to the current standard care in the UK. Whilst these
results are specific to the Tayside region, the study highlights that there
is a need for further investigation to understand how these strategies
would perform elsewhere. Governments wishing to achieve the 2030
HCV elimination target must shape central policies based on the ef-
fectiveness and cost-effectiveness of different screening strategies at a
sub-national level. They should, therefore, invest in further research to
enable extensive data collection across regions thus allowing for more
comprehensive, tailored and cost-effective decision-making.
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